Cancer-fighting virus shows promise in early clinical trial

July 8, 2007

A virus that has been specifically designed by scientists to be safe to normal tissue but deadly to cancer is showing early promise in a preliminary study, researchers said at the ESMO Conference Lugano (ECLU), Switzerland.

The virus, called NV1020, is a type of herpes simplex virus modified so that it selectively replicates in virus cells, killing them in the process.

“It doesn’t replicate in normal, healthy cells, so our hope is that it will help fight cancers without causing side-effects in the rest of the body,” said Dr. Axel Mescheder, VP Clinical Research & Development, from the Munich-based biotech company MediGene. The study is conducted in seven leading US-cancer centers, with Dr. Tony Reid from the University of California in San Diego, CA as Principal Investigator. Dr. Mescheder presented preliminary safety and efficacy results and a case report from this ongoing clinical trial in patients with colorectal cancer metastatic to the liver at the meeting.

Dr. Mescheder’s poster presentation described the case of a patient whose cancer had spread to 10 different places around the liver and four in the lungs. He was given the virus treatment in four weekly infusions direct into blood stream, followed by two cycles of approved chemotherapy.

Six months after treatment, scans showed the liver masses had nearly disappeared. “The reduction in the tumor masses was really impressive in this patient,” Dr. Mescheder said. “The hepatic masses almost disappeared.”

The patient survived for 12 months after treatment.

“In the current study, the scientists are testing the treatment in patients with colorectal cancer that have not responded to chemotherapy and where the cancer has spread to the liver,” Dr. Mescheder said. “We are hoping to extend overall survival.”

So far, the findings are looking positive. The treatment seems very tolerable for patients and safe. “The results are really quite encouraging at this early stage,” he said.

Almost 40% of patients with colorectal cancer ultimately die from metastatic disease, where the cancer spreads to other parts of the body. Most of the spreading occurs to the liver and 15% of patients have liver metastases at the time of diagnosis.

The latest human results reported today follow testing in the lab and in animals where the virus was shown to be effective at killing colorectal cancer cells and liver cancers.

Source: European Society for Medical Oncology

Explore further: Researchers bring an engineering approach to systems biology efforts

Related Stories

Hepatitis B virus mutations may predict risk of liver cancer

July 2, 2009

Certain mutations in the DNA of the hepatitis B virus (HBV) are associated with the development of liver cancer and may help predict which patients with HBV infections are at increased risk of the disease, according to a ...

Androgen receptor may explain male dominance in liver cancer

May 19, 2010

A University of Rochester study helps to explain why men get liver cancer more often than women and opens the door for a new treatment pathway, by showing a direct link between the androgen receptor, which is more active ...

Recommended for you

How the finch changes its tune

August 3, 2015

Like top musicians, songbirds train from a young age to weed out errors and trim variability from their songs, ultimately becoming consistent and reliable performers. But as with human musicians, even the best are not machines. ...

Machine Translates Thoughts into Speech in Real Time

December 21, 2009

( -- By implanting an electrode into the brain of a person with locked-in syndrome, scientists have demonstrated how to wirelessly transmit neural signals to a speech synthesizer. The "thought-to-speech" process ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.